Measurable disease evaluation in patients with myeloma Journal Article


Author: Roshal, M.
Article Title: Measurable disease evaluation in patients with myeloma
Abstract: Recent years saw significant breakthroughs in treatment of multiple myeloma. Durable remissions are now seen in a significant proportion of patients with the previously uniformly incurable and progressive disease. Yet because of deep suppression of the neoplastic myeloma clones by the newer therapies, older disease monitoring techniques are insufficient to distinguish between the patients at high risk of imminent relapse and those in whom durable remission is expected. This review briefly describes prognostic and therapeutic implications of measurable disease (MRD) evaluation, explains why deep MRD evaluation is needed for patients without morphologic evidence of disease, and reviews the state of the art of evaluation of myeloma MRD by flow cytometry. © 2020
Keywords: review; flow cytometry; bone marrow; validation study; minimal residual disease; blood analysis; antibody detection; conceptual framework; myeloma; cancer prognosis; prognosis; human; priority journal; disease assessment; measurable residual disease
Journal Title: Best Practice and Research: Clinical Haematology
Volume: 33
Issue: 1
ISSN: 1521-6926
Publisher: Elsevier Inc.  
Date Published: 2020-03-01
Start Page: 101154
Language: English
DOI: 10.1016/j.beha.2020.101154
PUBMED: 32139019
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Mikhail Roshal
    92 Roshal